AI ScreeningAI ChatPricing
  1. US-listed companies
  2. Intra-Cellular Therapies, Inc.
  3. Financials
  4. Total non-current liabilities

Intra-Cellular Therapies, Inc.【ITCI】

Market cap
$13.4B
P/E ratio
SummaryFinancials
Period EndTotal non-current liabilities (Million USD)YoY (%)
Dec 31, 202413-4.34%
Dec 31, 202313-13.88%
Dec 31, 202215-17.14%
Dec 31, 202119-20.87%
Dec 31, 202024+18.27%
Dec 31, 201920+525.08%
Dec 31, 20183+12.40%
Dec 31, 20173-0.99%
Dec 31, 20163+79.61%
Dec 31, 20152

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)